Microdosing: The Protocols, and What the Evidence Actually Shows

Microdosing is hugely popular and the anecdotes are glowing - but the controlled evidence is far more mixed. The common protocols, the dosing, the placebo problem, and the real risks, stated honestly.

Microdosing - taking a sub-perceptual amount of a psychedelic on a schedule - is one of the most popular ideas in the psychedelic space and one of the least settled. The personal accounts are enthusiastic; the controlled science is much more cautious. This is an honest look at both: the protocols people follow, and what the evidence actually supports.

What "microdose" means

A microdose is sub-perceptual - small enough that you can go about a normal day without feeling "high." Typical ranges:

• LSD: ~5-15 µg
• Psilocybin (dried cubensis): ~0.1-0.3 g

The whole premise is that you should not trip. If you feel noticeably altered, that's a regular low dose, not a microdose - and the amount should come down.

The common protocols

Protocols mostly exist to build in off-days, because tolerance to psychedelics develops fast and would blunt daily dosing:

• Fadiman protocol: dose one day on, two days off (a roughly every-third-day cadence), often for a number of weeks followed by a break.
• Stamets stack: a psilocybin-based stack (commonly paired with niacin and lion's mane), typically four days on, three off.
• Every-other-day and similar variants.

Most thoughtful approaches also cycle - several weeks on, then a meaningful break - both to limit tolerance and to re-check whether it's actually doing anything.

What the evidence actually shows

Here's where honesty matters. Two things are simultaneously true:

1. Observational and survey studies (people reporting their own experience) frequently find improvements in mood, focus, and creativity.
2. Placebo-controlled studies - where people don't know whether they're getting a microdose or a blank - tend to find that much of the benefit is explained by expectancy (placebo). The most striking example is a large self-blinding citizen-science study (Szigeti et al., 2021) in which microdosers improved on various measures - but so did the placebo group, to a strikingly similar degree.

The fair summary: microdosing is popular and broadly low in acute risk at these doses, but it is not yet well supported by rigorous evidence, and the placebo effect appears to be a large part of the reported benefit. That doesn't mean people's experiences aren't real to them - placebo effects are genuine - but it does mean the case for a specific pharmacological benefit is weak so far.

The real risks and unknowns

• Tolerance - why every protocol schedules off-days.
• A theoretical cardiac concern with frequent, long-term dosing. Psychedelics activate the 5-HT2B receptor, and chronic 5-HT2B activation by other drugs has historically been linked to heart-valve damage. Whether frequent microdosing poses a real cardiac risk is unknown - but it's the most cited reason to cycle rather than dose indefinitely, and to keep doses genuinely low.
• Contraindications - same as full doses (psychosis/bipolar history, certain medications, see interactions).
• Legality - these substances are controlled in most places regardless of dose.
• Dosing precision - micrograms of LSD and fractions of a gram of variable-potency mushrooms are genuinely hard to dose consistently.

A measured take

If you're going to try it: keep doses truly sub-perceptual, follow a protocol with off-days, cycle with real breaks rather than dosing indefinitely, respect the contraindications, and - given the evidence - hold your expectations lightly. The honest position isn't "it works" or "it's all placebo," but "the controlled evidence is mixed, the benefit may be largely expectancy, and the long-term safety of frequent use is not established."

The short version

Microdose = sub-perceptual doses (LSD ~5-15 µg, psilocybin ~0.1-0.3 g) on an off-day-based protocol (Fadiman, Stamets). Survey data looks positive; placebo-controlled data suggests much of the effect is expectancy. Cycle rather than dose indefinitely, mind the theoretical cardiac concern, respect the contraindications, and keep expectations grounded in what the evidence actually supports.

Educational only, not medical advice. Microdosing uses controlled substances at the same contraindication profile as full doses; the long-term safety of frequent use is not established.

Browse all articles →